MXPA04003773A - Uso de leptina para tratar lipoatrofia humana y metodo para determinar la predisposicion a dicho tratamiento. - Google Patents
Uso de leptina para tratar lipoatrofia humana y metodo para determinar la predisposicion a dicho tratamiento.Info
- Publication number
- MXPA04003773A MXPA04003773A MXPA04003773A MXPA04003773A MXPA04003773A MX PA04003773 A MXPA04003773 A MX PA04003773A MX PA04003773 A MXPA04003773 A MX PA04003773A MX PA04003773 A MXPA04003773 A MX PA04003773A MX PA04003773 A MXPA04003773 A MX PA04003773A
- Authority
- MX
- Mexico
- Prior art keywords
- leptin
- treatment
- treating human
- determining predisposition
- lipodystrophy
- Prior art date
Links
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title abstract 10
- 102000016267 Leptin Human genes 0.000 title abstract 6
- 108010092277 Leptin Proteins 0.000 title abstract 6
- 229940039781 leptin Drugs 0.000 title abstract 6
- 206010024604 Lipoatrophy Diseases 0.000 title 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 abstract 2
- 208000006132 lipodystrophy Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
Abstract
La leptina, analodos de leptina, y derivados de leptina se utilizan para tratar pacientes con lipodistrofia; la leptina es efectiva contra las condiciones de lipodistrofia para formas geneticas y adquiridas de la enfermedad; una cantidad terapeuticamente efectiva de leptina puede administrarse en una variedad de formas, incluyendo un vector que comprende secuencias de acido nucleico que codifican para la leptina; los metodos de la presente invencion contemplan la administracion de leptina, analogos de leptina, y derivados de leptina a pacientes que tienen aproximadamente 4ng/ml o menos antes del tratamiento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33639401P | 2001-10-22 | 2001-10-22 | |
| PCT/US2002/033875 WO2003034996A2 (en) | 2001-10-22 | 2002-10-22 | Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04003773A true MXPA04003773A (es) | 2004-07-30 |
Family
ID=23315890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04003773A MXPA04003773A (es) | 2001-10-22 | 2002-10-22 | Uso de leptina para tratar lipoatrofia humana y metodo para determinar la predisposicion a dicho tratamiento. |
Country Status (14)
| Country | Link |
|---|---|
| US (7) | US7183254B2 (es) |
| EP (2) | EP2219031B1 (es) |
| JP (7) | JP2005506994A (es) |
| AT (1) | ATE475094T1 (es) |
| AU (1) | AU2002359288B2 (es) |
| CA (1) | CA2464277C (es) |
| DE (1) | DE60237100D1 (es) |
| DK (2) | DK2219031T3 (es) |
| ES (2) | ES2350924T3 (es) |
| MX (1) | MXPA04003773A (es) |
| PL (1) | PL214862B1 (es) |
| PT (1) | PT2219031E (es) |
| SI (1) | SI2219031T1 (es) |
| WO (1) | WO2003034996A2 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE475094T1 (de) * | 2001-10-22 | 2010-08-15 | Amgen Inc | Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung |
| WO2006052608A2 (en) | 2004-11-01 | 2006-05-18 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
| US8716220B2 (en) | 2005-09-07 | 2014-05-06 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta |
| US8227408B2 (en) * | 2005-09-07 | 2012-07-24 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
| US20070066512A1 (en) * | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
| WO2008048691A2 (en) * | 2006-10-18 | 2008-04-24 | Amylin Pharmaceuticals, Inc. | Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders |
| EP2326339A4 (en) | 2008-05-21 | 2012-06-20 | Neurotez Inc | METHOD FOR TREATING PROGRESSIVE COGNITIVE DISORDER IN CONNECTION WITH NEUROFIBRILLARY TANGLES |
| US8501686B2 (en) * | 2008-06-05 | 2013-08-06 | University Of Michigan | Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects |
| US20110218141A1 (en) * | 2010-03-03 | 2011-09-08 | Hamrick Mark W | Leptin therapy to increase muscle mass and to treat muscle wasting conditions |
| ES2630031T3 (es) | 2010-09-28 | 2017-08-17 | Aegerion Pharmaceuticals, Inc. | Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada |
| ES2732475T3 (es) | 2011-07-08 | 2019-11-22 | Aegerion Pharmaceuticals Inc | Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida |
| EP4082541A1 (en) | 2012-09-27 | 2022-11-02 | The Children's Medical Center Corporation | Compounds for the treatment of obesity and methods of use thereof |
| WO2014203074A2 (en) | 2013-06-21 | 2014-12-24 | Alize Pharma Sas | Use of unacylated ghrelin, fragments and analogs thereof as antioxidant |
| PT3074033T (pt) | 2013-11-26 | 2019-02-08 | Childrens Medical Ct Corp | Compostos para o tratamento de obesidade e métodos de utilização dos mesmos |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| JP2015205846A (ja) * | 2014-04-22 | 2015-11-19 | 出光興産株式会社 | レプチン分泌促進剤 |
| TWI580690B (zh) * | 2014-08-25 | 2017-05-01 | The use of multidipins for the manufacture of pharmaceutical compositions for in vivo multipurpose effects | |
| TWI752920B (zh) | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| BR112019004715A2 (pt) | 2016-09-12 | 2019-07-16 | Aegerion Pharmaceuticals Inc | métodos para detectar anticorpos neutralizantes anti-leptina |
| GB202100311D0 (en) * | 2021-01-11 | 2021-02-24 | Univ Court Of The Univ Of Aberdeen | Treatment for Lipodystrophy |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5827734A (en) | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
| US5569743A (en) | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
| US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| EP0725079A1 (en) | 1995-01-31 | 1996-08-07 | Eli Lilly And Company | Anti-obesity proteins |
| US5554727A (en) | 1995-01-31 | 1996-09-10 | Eli Lilly And Company | Anti-obesity proteins |
| US5563245A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
| US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| US5559208A (en) | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
| US5569744A (en) | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
| US5567678A (en) | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
| US5594104A (en) | 1995-01-31 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
| US5525705A (en) | 1995-01-31 | 1996-06-11 | Eli Lilly And Company | Anti-obesity proteins |
| US5567803A (en) | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
| US5563243A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5574133A (en) | 1995-01-31 | 1996-11-12 | Eli Lilly And Company | Anti-obesity proteins |
| US5580954A (en) | 1995-01-31 | 1996-12-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5605886A (en) | 1995-01-31 | 1997-02-25 | Eli Lilly And Company | Anti-obesity proteins |
| EP0836620A1 (en) | 1995-01-31 | 1998-04-22 | Eli Lilly And Company | Anti-obesity proteins |
| US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5563244A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5594101A (en) | 1995-03-03 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
| US5719266A (en) | 1995-03-17 | 1998-02-17 | Eli Lilly And Company | Anti-obesity proteins |
| EP0736599A3 (en) | 1995-04-03 | 1996-12-11 | Takeda Chemical Industries Ltd | The rat obesity gene, its gene product and its production |
| WO1996031526A1 (en) | 1995-04-06 | 1996-10-10 | Amylin Pharmaceuticals, Inc. | Anti-obesity agents |
| US5614379A (en) | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
| GB9509164D0 (en) | 1995-05-05 | 1995-06-28 | Smithkline Beecham Plc | Novel compounds |
| ES2093593T1 (es) | 1995-05-05 | 1997-01-01 | Hoffmann La Roche | Proteinas obesas (ob) recombinantes. |
| WO1996035787A1 (en) | 1995-05-08 | 1996-11-14 | Chiron Corporation | Nucleic acids for treating obesity |
| CA2221824A1 (en) | 1995-05-26 | 1996-11-28 | Eli Lilly And Company | Rhesus ob protein and dna |
| AU6028396A (en) | 1995-06-07 | 1996-12-30 | Amgen, Inc. | Ob protein compositions and method |
| CA2224867A1 (en) | 1995-06-22 | 1997-01-09 | Eli Lilly And Company | Obesity protein intermediates and their preparation and use |
| JPH11508895A (ja) * | 1995-06-30 | 1999-08-03 | イーライ・リリー・アンド・カンパニー | 糖尿病を処置する方法 |
| MX9801159A (es) | 1995-08-17 | 1998-05-31 | Amgen Inc | Metodos de reduccion o para mantener los niveles reducidos de lipidos en la sangre usando composiciones de proteina ob. |
| WO1997016550A1 (en) | 1995-11-02 | 1997-05-09 | Bristol-Myers Squibb Company | Polypeptide fragments derived from the obese gene product |
| ES2339846T3 (es) | 1995-11-22 | 2010-05-26 | Amgen Inc. | Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob. |
| WO1997020933A2 (en) | 1995-12-06 | 1997-06-12 | Schering Corporation | MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS |
| WO1997038014A1 (en) | 1996-04-04 | 1997-10-16 | Amgen Inc. | Fibulin pharmaceutical compositions and related methods |
| TR199802534T2 (xx) | 1996-06-06 | 1999-03-22 | Smithkline Beecham P.L.C. | Leptin (OB Protein) fragmanlar� |
| US5922678A (en) * | 1996-06-28 | 1999-07-13 | Eli Lilly And Company | Methods for treating diabetes |
| EP1001768A1 (en) | 1996-08-30 | 2000-05-24 | Amgen Inc. | Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor |
| WO1998016545A1 (en) | 1996-10-11 | 1998-04-23 | Eli Lilly And Company | Therapeutic proteins |
| JP4175668B2 (ja) | 1996-12-20 | 2008-11-05 | アムジエン・インコーポレーテツド | Ｏｂ融合タンパク質組成物および方法 |
| CA2344623A1 (en) | 1998-10-02 | 2000-04-13 | Amgen Inc. | Method to determine a predisposition to leptin treatment |
| WO2000047741A1 (en) * | 1999-02-12 | 2000-08-17 | Amgen Inc. | Glycosylated leptin compositions and related methods |
| US6258932B1 (en) * | 1999-08-09 | 2001-07-10 | Tripep Ab | Peptides that block viral infectivity and methods of use thereof |
| JP2001199887A (ja) * | 1999-11-10 | 2001-07-24 | Takeda Chem Ind Ltd | 体重増加抑制剤 |
| ATE475094T1 (de) * | 2001-10-22 | 2010-08-15 | Amgen Inc | Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung |
| US6899892B2 (en) * | 2001-12-19 | 2005-05-31 | Regents Of The University Of Minnesota | Methods to reduce body fat |
-
2002
- 2002-10-22 AT AT02793811T patent/ATE475094T1/de not_active IP Right Cessation
- 2002-10-22 DE DE60237100T patent/DE60237100D1/de not_active Expired - Lifetime
- 2002-10-22 ES ES02793811T patent/ES2350924T3/es not_active Expired - Lifetime
- 2002-10-22 ES ES10165256T patent/ES2418954T3/es not_active Expired - Lifetime
- 2002-10-22 PL PL374301A patent/PL214862B1/pl unknown
- 2002-10-22 DK DK10165256.8T patent/DK2219031T3/da active
- 2002-10-22 EP EP10165256.8A patent/EP2219031B1/en not_active Expired - Lifetime
- 2002-10-22 SI SI200231031T patent/SI2219031T1/sl unknown
- 2002-10-22 EP EP02793811A patent/EP1444516B1/en not_active Expired - Lifetime
- 2002-10-22 MX MXPA04003773A patent/MXPA04003773A/es active IP Right Grant
- 2002-10-22 PT PT101652568T patent/PT2219031E/pt unknown
- 2002-10-22 JP JP2003537565A patent/JP2005506994A/ja active Pending
- 2002-10-22 CA CA2464277A patent/CA2464277C/en not_active Expired - Lifetime
- 2002-10-22 WO PCT/US2002/033875 patent/WO2003034996A2/en active Application Filing
- 2002-10-22 AU AU2002359288A patent/AU2002359288B2/en not_active Expired
- 2002-10-22 DK DK02793811.7T patent/DK1444516T3/da active
-
2003
- 2003-07-18 US US10/623,189 patent/US7183254B2/en active Active
-
2006
- 2006-11-29 US US11/606,805 patent/US20070099836A1/en not_active Abandoned
-
2010
- 2010-06-16 JP JP2010137501A patent/JP2010209114A/ja active Pending
-
2011
- 2011-05-09 US US13/103,294 patent/US8318666B2/en not_active Expired - Fee Related
-
2012
- 2012-11-05 US US13/669,324 patent/US20130190225A1/en not_active Abandoned
-
2014
- 2014-08-06 JP JP2014160718A patent/JP2014224142A/ja active Pending
-
2016
- 2016-05-13 US US15/154,749 patent/US20170095535A1/en not_active Abandoned
- 2016-05-31 JP JP2016108936A patent/JP2016190855A/ja not_active Withdrawn
- 2016-08-04 JP JP2016153889A patent/JP2016190872A/ja active Pending
-
2018
- 2018-07-27 JP JP2018141461A patent/JP6764906B2/ja not_active Expired - Lifetime
- 2018-11-19 US US16/195,661 patent/US20190321447A1/en not_active Abandoned
-
2019
- 2019-12-24 JP JP2019232609A patent/JP2020055868A/ja not_active Withdrawn
-
2020
- 2020-02-05 US US16/782,773 patent/US20200268853A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04003773A (es) | Uso de leptina para tratar lipoatrofia humana y metodo para determinar la predisposicion a dicho tratamiento. | |
| NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| GR3024787T3 (en) | Levobupivacaine useful for managing chronic pain | |
| MX348062B (es) | Mutantes que degradan proteoglicanos para tratamiento del snc. | |
| WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
| MX2008001520A (es) | Composiciones de tizanidina y metodos de tratamiento usando las composiciones. | |
| ATE422357T1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
| MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
| HU213677B (en) | Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them | |
| BR9912609A (pt) | Métodos de uso de um análogo de somatostatina | |
| EA200501549A1 (ru) | Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца | |
| AP1896A (en) | The method of treating cancer | |
| BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
| HUP9903679A2 (hu) | Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására | |
| BR0311180A (pt) | Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos | |
| WO2003045322A3 (en) | Method for treating and preventing pancreatitis | |
| WO1994024279A3 (en) | Agents for the prevention and treatment of huntington's disease and other neurological disorders | |
| NO984196D0 (no) | Fremgangsmåte for behandling av stoffmisbruk | |
| UA66749C2 (en) | Actin-resistant variants of human dnase i, isolated nucleic acid, a method for treatment of patients suffering from pulmonary diseases | |
| DE69307702D1 (de) | Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit | |
| HUP9903685A2 (hu) | Olanzapin alkalmazása túlzott agresszivitás kezelésére szolgáló gyógyszerkészítmények előállítására | |
| 周立群 | How to Promote the Therapeutic Effect of Auriculotherapy in the Treatment of Vascular Hypertension? | |
| NO961180L (no) | Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom | |
| WO2001041703A3 (en) | Method for treating allergic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |